Newsletters (Portuguese only)

 

NL - 2019 Editions Highlights
Edition 6 21000 patients
Edition 5 Informed (Re)Consent
Edition 4 New Protocol MYOSITIS
Edition 3 Osteoarthritis protocol
Edition 2 11 years of Reuma.pt
Edition 1 Total at the end of 2018

 

NL - 2018 Editions Highlights
Edition 12 20000 patients
Edition 11 Rheumatoid arthritis protocol
Edition 10 Drugs and adverse events
Edition 9 Access to the patient's area
Edition 8 Scleroderma
Edition 7 Prescription and dispensing of biological drugs
Edition 6 19000 patients
Edition 5 General Data Protection Regulation
Edition 4 End of mandate, accounting period
Edition 3 Biosimilar drugs
Edition 2 10 years of Reuma.pt
Edition 1 Total at the end of 2017

 

NL - 2017 Editions Highlights
Edition 12 Use of Reuma.pt by patients
Edition 11 18000 patients
Edition 10 Vasculitis
Edition 9 Adverse events associated with biologic drugs
Edition 8 Dates of diagnosis and disease onset
Edition 7 Loss to follow-up
Edition 6 RAID
Edition 5 Geographical distribution of Reuma.pt patients
Edition 4 Early arthritis
Edition 3 Biological drugs
Edition 2 9 years of Reuma.pt
Edition 1 Total at the end of 2016

 

NL - 2016 Editions Highlights
Edition 12 Clinical trials: Biomarkers in ankylosing spondylitis
Edition 11 1st Edition of Janssen Innovation Award
Edition 10 End of mandate, accounting period
Edition 9 Patients adherence to Reuma.pt
Edition 8 Data extraction
Edition 7 Sjögren´s syndrome
Edition 6 15000 patients
Edition 5 Hepatitis B and C serology tests
Edition 4 Patient's self assessment forms
Edition 3 Biological drugs
Edition 2 Biosimilar drugs
Edition 1 Security of the biological therapies

 

NL - 2015 Editions Highlights
Edition 12 Total at the end of 2015
Edition 11 Scientific articles
Edition 10 100 000 visits
Edition 9 Scleroderma
Edition 8 Active TB disease
Edition 7 Clinical trial for patients with gonarthrosis
Edition 6 Lab analysis
Edition 5 Pediatric rheumatology
Edition 4 Frequently Asked Questions
Edition 3 Clinical trials: GO-DACT
Edition 2 Osteoarthritis
Edition 1 Biological treatments

 

NL - 2014 Editions Highlights
Edition 12 Total at the end of 2014
Edition 11 Visits at the start of biological treatments
Edition 10 Vasculitis
Edition 9 End of mandate, accounting period
Edition 8 Apps on the Reuma.pt website
Edition 7 Selection of patients through filters
Edition 6 Analysis of data inconsistencies
Edition 5 Reuma.pt outputs
Edition 4 Adverse drug reactions
Edition 3 Sharing patients between centres
Edition 2 6 years of Reuma.pt
Edition 1 Autoinflammatory syndromes

 

NL - 2013 Editions Highlights
Edition 4 10.000 patients and 60.000 visits
Edition 3 "Hospital do Futuro 2012/2013" Awards
Edition 2 Patient's self assessment forms
Edition 1 Statistical reports, a new tool at your disposal in Reuma.pt

 

NL - 2012 Editions Highlights
Edition 3 The Reuma.pt is already over 6000 patients, having grown 50% in just over a year. The number of registered visits is about 38.000
Edition 2 Inconsistencies report, a new tool available to increase data quality
Edition 1 Reuma.pt web version - available from April 16

 

NL - 2011 Editions Highlights
Edition 6 The Reuma.pt has as total of 4749 patients, 1500 treated with biological agents!
Edition 5 It is essential to fill in DAS28 components at every visit of patients with RA
Edition 4 The Reuma.pt grew 25% in last half year, having now almost 4000 patients!!
Edition 3 It is essential to introduce the data for the visit before the beginning of treatment with biological agent
Edition 2 It is essential to enter data currently missing in Reuma.pt!
Edition 1 The Reuma.pt already includes more than 15000 visits, > 4 visits / patient on average!

 

NL - 2010 Editions Highlights
Edition 1 The Reuma.pt already surpassed the threshold of 3000 patients!!